000			02399nam a22001577a 4500
082			_a610
100			_aShahjehan, Ayesha _9120893
245			_aPost-Discharge symptoms and analysis for COVID-19 patients / _cAyesha Shahjehan
264			_aIslamabad : _bSMME- NUST; _c2022.
300			_a65p. _bSoft Copy _c30cm
500			_aCoronavirus was initially recognized as human COVID by researchers in 1965. Different strains of coronavirus appeared in the following years MERS, SARS-1. Thousands of cases were reported in individuals that to led many casualties, in 2019. New strains of coronavirus emerged, known as covid-19that started to spread from Wuhan, China. It was labeled a worldwide epidemic by the World Health Organization (WHO) in March 2020, the first since 2009. Patients with covid-19 experienced gentle to extreme indications like fever, cough, weariness, shortness of breath, migraine, loose bowels, nausea, and vomiting. As SARS cov-2 is a novel infection, initially the infected patients were treated in a single room along with the utilization of antiviral medication, including oseltamivir, ribavirin, and ganciclovir, lopinavir, and ritonavir to decrease the viral burden. Indications during the contamination may not resolve unexpectedly grumble about persistent side effects, even a long time after the disease. The research is based on observing the symptoms of COVID and postCOVID in patients who perform PCR tests at a hospital. Sample of 26 males and 34 females. Services were taken and their symptoms were noted during and after the quarantine. During the assessment of the covid-19 pandemic, it was seen that overall unexpected issues have gotten even after the onset of intensive covid-19. The prolonged aftereffect stays unexplained. The point of this examination is to represent the persistent symptoms in patients who were released from the health center and to explore the related element of danger. The impact of the study is fundamental in investigating the components and potential persistent post-COVID disorder. It presents a system of procedures for prognosis and handling of patients with suspected or affirmed persevering post-COVID conditions.
650			_aMS Biomedical Sciences (BMS)
700			_aSupervisor : Dr. Muhammad Asim Waris _9119524
856			_uhttp://10.250.8.41:8080/xmlui/handle/123456789/31837
942			_2ddc _cTHE
999			_c607924 _d607924